Mayne Pharma to Invest $65m in Manufacturing Expansion

Published on: 

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and Management-09-02-2015, Volume 11, Issue 9

Mayne Pharma plans to double oral-dose manufacturing space and expand contract services.

Mayne Pharma has announced plans to invest $65 million to expand facilities and equipment at its site in Greenville, NC. In an Aug. 27, 2015 statement, the company’s reported plans for the greenfield construction of a 126,000-sq-ft, large-scale oral-dose manufacturing facility, along with the repurposing of existing space to expand contract services.

When the new facility becomes fully operational in 2018, it will more than double the company’s manufacturing capacity in the United States and will include the hiring up to 110 more scientists, quality assurance specialists, manufacturing operators and technicians.

The new facility will be constructed on a campus that houses Mayne Pharma’s products business, along with its contract development and manufacturing (CDMO) business, Metrics Contract Services. Metrics was acquired in 2012 by Mayne Pharma.

The new facility will allow Mayne Pharma to expand development, manufacturing and packaging operations for generic and specialty drug products, and expand services to Metrics clients with commercial manufacturing requirements, the company reports.


The company reports that it has worked with state and local governmental agencies in support of the capital expansion and secured funding and incentives worth up to $2.7 million.

Source: Metrics Contract Services